RAF709

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

BRAF inhibitor, cRAF inhibitor

Related drugs:

NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	RAF709 Sensitive: D – Preclinical RAF709 Sensitive : D	RAF709 Sensitive: D – Preclinical RAF709 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	RAF709 Sensitive: D – Preclinical RAF709 Sensitive : D	RAF709 Sensitive: D – Preclinical RAF709 Sensitive : D
NRAS Q61L	Melanoma	NRAS Q61L	Melanoma	RAF709 Sensitive: D – Preclinical RAF709 Sensitive : D	RAF709 Sensitive: D – Preclinical RAF709 Sensitive : D

Associations
(3)